115378-21-7

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-amino-5-bromo-3-methoxybenzoate is used as a key intermediate in the synthesis of new drug compounds due to its unique structural features and potential biological activities. Its presence of a bromine atom and other functional groups allows for the development of compounds with specific therapeutic properties.
Used in Drug Discovery and Development:
methyl 2-amino-5-bromo-3-methoxybenzoate is employed as a valuable asset in drug discovery and development processes, particularly for its anti-inflammatory and analgesic properties. Its ability to modulate inflammatory responses and alleviate pain makes it a promising candidate for the treatment of various conditions that involve inflammation and pain.
Used in Treatment of Diseases and Medical Conditions:
Methyl 2-amino-5-bromo-3-methoxybenzoate is explored for its potential use in the treatment of a range of diseases and medical conditions. Its biological activities suggest that it could be instrumental in managing or treating disorders that benefit from anti-inflammatory and analgesic effects, although further research is necessary to confirm its efficacy and safety in clinical settings.

Upstream product

• 5121-34-6 methyl 2-amino-3-methoxybenzoate 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 5307-17-5 methyl 3-methoxy-2-nitrobenzoate 
• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 115378-20-6 3-methoxy-2-pivalamidobenzoic acid 
• 90-04-0 2-methoxy-phenylamine 
• 33768-49-9 N-(2-methoxyphenyl)pivalamide 
• 3177-80-8 2-amino-3-methoxybenzoic acid 

Downstream Products

• 115378-24-0 5-Bromo-2-(3-chloro-5-hydroxy-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-3-methoxy-benzoic acid methyl ester 
• 115378-26-2 2-(5-Acetoxy-3-chloro-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)-5-bromo-3-methoxy-benzoic acid methyl ester 
• 115378-27-3 2-(5-Acetoxy-1,4-dioxo-3-phenylselanyl-1,4-dihydro-naphthalen-2-yl)-5-bromo-3-methoxy-benzoic acid methyl ester 
• 697762-67-7 methyl 5-bromo-2-chloro-3-methoxybenzoate 
• 906095-47-4 2-amino-5-bromo-3-hydroxybenzoic acid hydrobromide 
• 864292-36-4 6-bromo-2,4-dichloro-8-methoxyquinazoline 
• 1415470-79-9 (2S,3R,4R,5S,6R)-2-(6-(4-ethylbenzyl)-7-chloro-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-82-4 (2S,3R,4R,5S,6R)-2-(8-chloro-7-(4-ethylbenzyl)chroman-5-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1415470-83-5 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-ethoxybenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1415467-76-3 5-bromo-2-chloro-3-methoxybenzoic acid 

Relevant academic research and scientific papers

Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes

Sodium-dependent glucose co-transporter 2 (SGLT2) has emerged as a promising drug target for the treatment of type 2 diabetes, and recently, several SGLT2 inhibitors have been approved for clinical use. A series of molecules with a C-aryl glucoside scaffo

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which

NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF

Provided is a compound superior in an autotaxin inhibitory action and the like, effective as a prophylactic or therapeutic drug for diseases involving ATX. The present invention relates to a compound represented by the following formula (I): [wherein each symbol is as described in the DESCRIPTION], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving ATX.

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Benzoxazole carboxamides for treating CINV and IBS-D

Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.

NOVEL 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR

Provision of a compound having an anti-HIV activity, particularly an integrase inhibitory activity.A 4-oxoquinoline compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.The present invention also relates to a pharmaceutical composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; an integrase inhibitor, an antiviral agent, anti-HIV agent and the like, which contains the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof as an active ingredient; an anti-HIV composition containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof, and one or more other kinds of anti-HIV activity substances as active ingredients; an anti-HIV agent containing the 4-oxoquinoline compound or a pharmaceutically acceptable salt thereof as an active ingredient, which is used for a multiple drug therapy with other anti-HIV agent(s), and the like.

4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Synthesis of the Aglycones of the Ravidomycin Family of Antibiotics

The preparation of the aglycones of the ravidomycin family of antibiotics is described, involving the palladium-catalysed coupling of appropriate stannanes with a common tetracyclic bromide (5), the synthesis of which involved Meerwein coupling of an anil